China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.

China-based antibody drug developer Trinomab closed a RMB450m ($69.3m) series A round yesterday featuring pharmaceutical company China Medical System and contract drug development and manufacturing organisation WuXi Biologics, DealStreetAsia reported.

GL Ventures, the venture capital branch of hedge fund manager Hillhouse Capital, led the round, which also featured state-owned enterprise group Guolian Group, while WuXi Biologics took part through its industry investment fund.

Trinomab is using its HitmAb technology platform to develop antibody-based therapeutics to treat infectious and autoimmune diseases,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn